Vigilance Communication To Industry - SAHPRA

Pharmacovigilance Communication To Industry

Document NumberTitleCategoriesDate UpdatedVersionUnitsLinkdoc_categories_hfilterdoc_tags_hfilter
VETPV 01 2025/26Format for Dear Veterinary Professional Letter Template29/09/20261, Downloadcommunication-to-industrypharmacovigilance veterinary-medicines
PV 03-2026/27SAHPRA Integrates the National Immunisation Safety Expert Committee (NISEC) into its Governance and Administrative Framework15/09/20261, Downloadcommunication-to-industryclinical-evaluations-management pharmacovigilance
PV02-2026/27Pharmacovigilance and Clinical Trials Units | SAHPRA Industry Consultation on e-Reporting VigiFlow Platform27/07/20261, , Downloadcommunication-to-industryclinical-evaluations-management clinical-trials pharmacovigilance
PV01-2026/27Mandatory call up for holders of certificates of registration to submit post marketing adverse event reports for human medicines (serious and non-serious) through Industry e- Reporting VigiFlow module24/06/20261, Downloadcommunication-to-industryinspectorate pharmacovigilance
PV03-2025/26Request for Submission of Latest PSMF and Product/PV Resourcing Information04/11/20251, Downloadcommunication-to-industryinspectorate pharmacovigilance
PV02-2025/26Amendment of the training dates for the MedDRA Training10/10/20251Downloadcommunication-to-industrypharmacovigilance
Pharmacovigilance Process of Issuing Safety Recommendations to Applicants/HCRS For Implementation29/02/20241Downloadcommunication-to-industrypharmacovigilance
Electronic Submission Of Adverse Drug Reaction (ADR) Reports – E2b Reporting18/08/20221Downloadcommunication-to-industrypharmacovigilance
21.9Communication to industry on metformin-containing medicines, 14/10/20201Downloadcommunication-to-industry safety-alertspharmacovigilance
21.8Communication to industry on ranitidine-containing medicines, 22/10/20201Downloadcommunication-to-industry safety-alertspharmacovigilance
Communication to industry on Post Marketing Reporting of ADRs guideline31/05/20211Downloadcommunication-to-industrypharmacovigilance